IPC Designated Lead Authority for Transplant Safety Surveillance
To address crucial surveillance gaps surrounding biological materials and tissue handling, the Union Ministry of Health and Family Welfare officially launched the Biovigilance Programme of India (BvPI). Announced by Union Minister of State for Health and Family Welfare Anupriya Patel during the inauguration of the 6th National Pharmacovigilance Week, the regulatory mandate designates the Indian Pharmacopoeia Commission (IPC) as the national coordinating agency responsible for tracking adverse biological events, unexpected graft reactions, and tissue preservation complications across transplant centers nationwide.
Overview: Structural Scope of India’s Patient-Safety Vigilance Architecture
| Vigilance Vertical | Statutory Lead & Core Objective | Targeted Clinical Assets / Subjects |
| Pharmacovigilance (PvPI) | Indian Pharmacopoeia Commission (IPC) | Adverse Drug Reactions (ADRs) & pharmaceutical safety |
| Materiovigilance (MvPI) | IPC / Indian Council of Medical Research (ICMR) | Adverse events related to medical devices & implants |
| Biovigilance (BvPI) | Indian Pharmacopoeia Commission (IPC) | Organ & tissue transplants, storage fluids, & biologicals |
| Coverage Aperture | Dual Pathway: Covers living donors & organ recipients | Allografts, corneas, stem cells, & preservation media |
| Reporting Channels | ADRMS digital platform, mobile app, & multi-lingual helpline | Primary, secondary, & tertiary healthcare institutions |
Bridging Longitudinal Gaps Across Organ and Tissue Transplantation
Until now, India’s patient-safety oversight comprised the Pharmacovigilance Programme of India (PvPI) for pharmaceuticals and the Materiovigilance Programme of India (MvPI) for medical devices. However, biological products—such as specialized tissue preservation media, immunosuppressive induction biologics, allografts, corneal tissues, and cellular therapies—lacked a dedicated national reporting framework to systematically monitor biological variance or contamination.
BvPI directly bridges this gap by covering the entire clinical continuum for both living donors and transplant recipients. By establishing standardized reporting templates for hospital transplant coordination committees, the IPC aims to capture early signals of unexpected graft failure, biological incompatibilities, or preservation media contamination before widespread clinical harm occurs.
Digital Architecture and Release of 7th National Formulary of India
To facilitate frontline reporting without tertiary-tier delays, the IPC is expanding its Adverse Drug Monitoring System (ADRMS) portal, mobile application, and QR-code reporting tools to primary and regional healthcare centers. The digital network is supported by a multilingual interactive voice response (IVR) helpline, ensuring seamless event reporting across public and private hospitals.
Alongside the biovigilance launch, the Union Minister released the 7th Edition of the National Formulary of India (NFI 2026) in both print and digital formats. Highlighting India’s growing regulatory standing, officials noted that Indian Pharmacopoeia standards are now recognized across more than 25 countries, positioning the new biovigilance framework to generate high-quality domestic scientific evidence to guide international transplant safety standards.